Status In progress
Process CDF Review
ID number 1584

Provisional Schedule

Committee meeting: 1 07 April 2020
Expected publication 24 June 2020

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department of Health
  NHS England
  Welsh Government
Professional groups British Thoracic Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Allergan (docetaxel, gemcitabine, paclitaxel, pemetrexed, vinorelbine) (CAU not returned, not participating)
  Celgene (paclitaxel) (CAU not returned, not participating)
  Dr Reddy’s Laboratories (docetaxel) (CAU not returned, not participating)
  Eli Lilly (gemcitabine, pemetrexed) (CAU not returned, not participating)
  Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Medac GmbH (docetaxel, gemcitabine, paclitaxel, vinorelbine) (CAU not returned, not participating)
  Peckforton Pharmaceuticals (paclitaxel) (CAU not returned, not participating)
  Pierre Fabre (vinorelbine) (CAU not returned, not participating)
  Sandoz (cisplatin) (CAU not returned, not participating)
  Sanofi (docetaxel) (CAU not returned, not participating)
  Seacross pharmaceuticals (docetaxel,
  pemetrexed) (CAU not returned, not participating)
  Sun Pharma (carboplatin,
  gemcitabine) (CAU not returned, not participating)
  Teva UK (docetaxel) (CAU not returned, not participating)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
28 November 2019 Invitation to participate
30 August 2019 In progress, Pembrolizumab within its marketing authorisation for non-small cell lung cancer.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance